Summary
The ability of leukemic cells to phosphorylate cytosine arabinoside (araC) and retain the triphosphate form of the drug (araCTP) is strongly predictive of remission duration for patients with acute nonlymphocytic leukemia who are treated with araC-based maintenance therapy. An increase in the intensity of therapy improves the overall median duration of remission, the increased intensity of therapy being especially beneficial for patients whose leukemic cells do not retain araCTP. This alteration in therapy reduces the prognostic significance of leukemic cell araCTP retention. Further, it seems that the use of high-dose araC as intensive consolidation therapy and the administration of conventional-dose araC by continuous infusion make it possible to further reduce or even abrogate the adverse prognostic significance of low leukemic cell retention of araCTP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bennett JM, Catovsky D, Daniel MT, et al (1976) Proposals for the classification of the acute leukemias. Br J Haematol 33:451
Chu TC, Arlin Z, Clarkson BD, Philips FS (1977) Metabolism of 1-β-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res 37:3561
Early AP, Preisler HD, Slocum S, Rustum YM (1982) A pilot study of high-dose 1-β-arabinosidefuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 42:1587
Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York
Kessel D, Hall TC, Rosenthal D (1969) Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro. Cancer Res 29:459
Preisler H, Raza A, Azarnia N, et al (1978) Role of early intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia. Proc Am Soc Hematol Abstr 730 (Dec 3)
Preisler HD, Bjornsson S, Henderson ES et al (1979) Treatment of acute nonlymphocytic leukemia: Use of anthracycline-cytosine arabinoside induction therapy and a comparison of two maintenance regimens. Blood 53:455
Preisler HD, Brecher M, Browman G, et al (1982) The treatment of acute myelocytic leukemia in patients 30 years of age and younger. Am J Hematol 13:189
Preisler HD, Rustum Y, Priore R (1984) Relationship between leukemic cell metabolism of cytosine arabinoside and the outcome of chemotherapy for acute myelocytic leukemia. Eur J Cancer Clin Oncol 20:1061
Preisler HD, Raza A, Azarnia N, Browman G (1984) Remission duration in acute nonlymphocytic leukemia: practical and theoretical considerations in minimal residual disease in acute leukemia. In: Lowenberg B, Hagenbeck A (eds) Nijhoff, Boston, The Hague p 359
Preisler HD, Raza A, Rustum Y, Browman G (1985) The treatment of patients with acute nonlymphocytic leukemia in remission. Semin Oncol 12 [Suppl 3]:91
Preisler HD, Raza A, Browman G et al (1985) Remission duration in acute nonlymphocytic leukemia: intensity of therapy, AraCTP retention and cytogenetics as prognostic factors. Proc Am Assoc Cancer Res 26:711
Preisler HD, Raza A, Early A, Kirshner J, Brecher M, Freeman A, Rustum Y, Azarnia N et al. (1986) Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol (in press)
Rai K, Brunner K, Obrecht JP, et al (1981) Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 58:1203
Rees JKH, Sandler TM, Challenger J, Hayhoe FGJ (1977) Treatment of acute myeloid leukemia with a triple cytotoxic regime: DAT. Br J Cancer 36:770
Rustum YM (1978) Metabolism and intracellular retention of 1-β-D-arabinofuranosyl cytosine as predictor of response of animal tumors. Cancer Res 38:543
Rustum YM, Preisler HD (1979) Correlation between leukemic cell retention of 1-β-D-arabinosylcytosine-5′-triphosphate and response to therapy. Cancer Res 39:42
Slevin ML, Piall EM, Aherne GW, et al (1982) The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol [Suppl 1]: 157
Yates JP, Wallace HJ, Ellison PR, Holland JF (1973) Cytosine arabinoside and daunorubicin therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57:485
Author information
Authors and Affiliations
Additional information
This work was supported by grants CA 41285, CA 21071. The authors would also like to thank Dr George Royer and the Upjohn Company for partial support for the studies described here
Rights and permissions
About this article
Cite this article
Preisler, H.D., Rustum, Y.M., Azarnia, N. et al. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside. Cancer Chemother. Pharmacol. 19, 69–74 (1987). https://doi.org/10.1007/BF00296260
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00296260